Filgotinib Decreases Both Vertebral Body and Posterolateral Spine Inflammation in Ankylosing Spondylitis: Results from The TORTUGA Trial

Maksymowych et al., assessed the effects of filgotinib on inflammatory and structural changes at various spinal locations, based on MRI measures in patients with active ankylosing spondylitis in the TORTUGA trial. Correlations between changes in the inflammation score and clinical outcomes were also evaluated.

This study suggested that treatment with filgotinib reduced spinal inflammation in diverse spinal locations that are highly relevant to spinal function and mobility, particularly in facet joints and posterolateral elements. However, there was no correlation between the change in inflammation scores and baseline functionality. Comparison of the changes in total spine and regional inflammation scores between treatment groups produced significant outcomes.